Emanuele Crupi: Exploring HER2 in Urothelial Carcinoma: Challenges, Therapies, and Future Directions
Emanuele Crupi, Postdoctoral Fellow in GU Med. Oncology at the University of Texas M.D. Anderson Cancer Center, shared on LinkedIn about a recent paper by Daniele Raggi et al. published on Nature:
“Thrilled to share our new review in Nature Reviews Urology:
HER2 and urothelial carcinoma: current understanding and future directions
HER2 is a well-established biomarker in breast and gastric cancer, but its role in urothelial carcinoma is more complex. Up to 68% of tumors may express HER2 when HER2-low cases are included, yet its prognostic and predictive value remains unsettled.
In this review, we:
- Explore the heterogeneity of HER2 expression across stages, histologies, and tumor sites.
- Highlight challenges in HER2 assessment and the urgent need for standardized testing.
- Summarize evidence from trials of HER2-targeted therapies — where early agents showed limited gains, but ADCs like trastuzumab deruxtecan (TDXd) and disitamab vedotin (DV) show meaningful activity, even in HER2-low tumors.
- Outline future opportunities, from refining HER2 thresholds to integrating composite biomarkers (FGFR3, NECTIN-4, PD-L1).
Read the full article.”
Title: HER2 and urothelial carcinoma: current understanding and future directions
Authors: Daniele Raggi, Emanuele Crupi, Filippo Pederzoli, Alberto Martini, Alberto Briganti, Omar Alhalabi, Peter H. O’Donnell, Jeffrey Ross, Shilpa Gupta, Ashish M. Kamat, Bishoy M. Faltas, Peter C. Black, Phillip E. Spiess, Petros Grivas, Jianjun Gao, Andrea B. Apolo, Robert A. Huddart, Andrea Necchi & Matthew D. Galsky
More posts featuring Emanuele Crupi.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023